

VTAMA CREAM

#1 PRESCRIBED

BRANDED TOPICAL TREATMENT FOR ADULTS WITH PLAQUE PSORIASIS*

6x the efficacy vs vehicle

In two 12-week pivotal studies, PGA success rate[^] was 36% and 40% for patients using VTAMA cream vs 6% and 6% for patients on vehicle.¹



Favorable safety and tolerability

In clinical studies, VTAMA cream showed a favorable and consistent safety profile and was well-tolerated, even on sensitive areas of skin.¹⁻³



~4 month off-treatment effect

In an open-label, long-term extension study, the median time to first disease worsening (defined as PGA \geq 2 [mild]) was 114 days (n=73).^{3,4}



*IQVIA National Prescription Audit (NPA) for the 3-month period ending 6/9/2023, reflecting estimates of real-world activity. All rights reserved.

Important Safety Information

Indication: VTAMA[®] (tapinarof) cream, 1% is an aryl hydrocarbon receptor agonist indicated for the topical treatment of plaque psoriasis in adults. **Adverse Events:** The most common adverse reactions (incidence \geq 1%) in subjects treated with VTAMA cream were folliculitis (red raised bumps around the hair pores), nasopharyngitis (pain or swelling in the nose and throat), contact dermatitis (skin rash or irritation, including itching and redness, peeling, burning, or stinging), headache, pruritus (itching), and influenza (flu).

GETTING YOUR PATIENT STARTED

To ensure patients receive VTAMA cream:

● Include:

- ICD 10 Code (ex. L40.0, L40.9)
- BSA %
- Previous tried and failed medications with timeframes
- Chart notes

● Confirm patient contact information

● Give patients the **MYVTAMA** card



Scan the
QR code to
learn more
about
MyVTAMA

VTAMA[®]
(tapinarof) cream 1%
(vee-TAM-uh)

You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see accompanying Prescribing Information in pocket.

© 2023 Dermavant Sciences, Inc. All rights reserved. All trademarks are the property of Dermavant Sciences, GmbH.
US-Vtama-2500488

[^]PGA success: PGA score of 0 or 1 and a ≥ 2 -grade improvement from baseline at week 12. Calculation: 36/6=6; 40/6=6.7

1. VTAMA (tapinarof) cream, 1%. Prescribing Information. Dermavant; 2022.

2. Strober B, Stein Gold L, Bissonnette R, et al. One-year safety and efficacy of tapinarof cream for the treatment of plaque psoriasis: results from the PSOARING 3 trial. J Am Acad Dermatol. 2022;87(4):800-806.

3. Stein Gold L, Kircik L, Lebwohl M, et al. Tapinarof cream 1% once daily for plaque psoriasis: favorable local tolerability in two pivotal phase 3 trials. Poster presented at: Innovations in Dermatology Conference; March 16–20, 2021; virtual.

4. Lebwohl M, Stein Gold L, Strober B, et al. Phase 3 trials of tapinarof cream for plaque psoriasis. N Eng J Med. 2021;385(24):2219-2229.